reeder
127
dysregulated
AT
CD44
gujral
1481
topoisom
administra
mammary
greif
ro
livant
fitzpatrick
agonist
fulvestrant
ERRP
reuter
chinnaiyan
panitumumab
potentially
targeting
vidaza
meningeal
mestre
p21
gray
5345
fojo
medicine
tinib
CXCR4
tumour
molecule
shown
1630
3109
AA
infusional
contribute
lowski
prince
reduce
350
synthetic
AH
tate
insight
1969
curcuminoid
sabel
wild
153
magalska
101
340
bladder
pab
breast
kappa
825
activity
apop
ifex
padget
LL
presence
naumann
myc
thology
maa
malaya
setting
trol
thank
parker
faslodex
type
killeen
motility
genesi
kapelari
trigger
phosphatase
plerixafor
estimate
biochemistry
smith
2002
dent
howell
death
reactive
ota
booth
569
anaplastic
proof
nature
supported
deregulation
there
heme
interfering
glycogen
NK
kuhn
transducer
madar
diferuloylmethane
medi
olsen
pertu
cen
pharma
dence
pollmann
diketone
vascular
houston
sensitivity
people
jeong
d’andrea
treated
temodar
1688
protection
source
oxidizing
certain
chromatin
outcome
humira
occur
synthase
508
LZ
anemia
ferraro
meeting
erbb2
ontak
directly
plenaxi
caspase
1554
HY
curcumin
EH
togenesi
bevaci
JL
SC
vari
citrate
gusterson
ali
136
confirmed
116
stimulation
inter
spohn
extensively
661
show
reducing
umbilical
sarva
581
jone
p21waf1
price
colored
grimm
pleo
upregulate
killing
ERK1
1975
african
pharmacal
1973
1991
starr
should
ovarie
HIF
cdk
everolimu
implicating
varga
halaven
involve
gonadotropin
HF
timur
los
blasiu
1033
ruxolitinib
IJ
carbonyl
ricker
bar
hooper
GADD
better
keep
editing
1541
cysteine
2723
doxo
loo
TJ
kondo
proapoptotic
siddiqui
cispla
interest
supply
frequently
osteoclasto
tubulin
lapa
raloxifene
undesirable
irreversible
5940
jaiswal
HB
BP
foster
biomarker
IAP
viable
mizushina
regulate
KL
mullally
phosphate
sci
349
764
clinical
lazaro
E3
chung
CM
hai
turner
137
integrin
index
gao
seibert
advantageou
bessarabova
TF
proposed
AMP
ubiquitin
differenti
tightly
SJ
fujii
tubulovillou
bexxar
garnett
nicholson
ety
NH2
known
era
subdivided
YX
1664
112
CIP1
affordability
goldin
ishino
sented
lym
gener
rent
debernardi
vivo
keratino
lichten
trench
maintenance
cizumab
correspondence
FK
DE
MV
SKOV3
961
PTP
nrf2
jevtana
interact
paracrine
haem
cialized
PS
chimica
chemi
table
recognize
seminar
green
cifically
line
spindle
yellow
emphasi
FLIP
moll
ecule
108
futreal
1001
SW
philadelphia
result
keyword
hussain
DTIC
kuppusamy
225
6744
142
330
paclitaxel
discov
biology
solution
somerase
stimuli
360
inhib
moiety
alpha
reflecting
MD
cooper
bate
wa
set
efudex
preclinical
biochemical
1988
ylation
JO
proleukin
sarcoma
syn
agent
conney
ET
met
zarnegar
apopto
DL
proangiogenic
dominantly
p38
bharti
oncogene1
ozdemir
353
toposar
could
expression
berg
1155
sriganth
naik
128
MH
hussein
hyperphosphorylated
preferen
duan
suggesting
ijbmb
almendro
yoon
278
bava
referred
YS
subunit
antibody
vation
plasminogen
interaction
tong
proteinase
research
dai
houghton
mdm2
center
sion
texa
ghosh
yakuchi
facilitate
1562
kappab
PK
archive
clofarabine
nagura
jing
YJ
synergistically
1557
ranga
1486
ozben
PDGF
vasion
metabolism
activator
inhibit
shimazaki
sensitive
biophysical
incubation
HDAC3
kuraya
both
angiogen
upregulation
squire
532
pound
metalloproteinase
blocked
overcome
moundhri
watt
although
period
mathew
important
proteasomal
dicato
U87MG
graft
tury
modula
sunitinib
targeted
rev
175
stimulated
halting
swaminathan
comparison
LR
2295
topoisomerase
1882
yuen
mainly
all
irinote
mitogen
indian
renehan
ription
manogaran
embryo
survivin
dysregula
redox
attach
british
MAPK
tropic
kraft
neuro
myeloma
zhao
sobol
pho
degradation
kuala
0052
pellet
2006
TNF
BMJ
pacheco
would
nostat
administered
epidermi
leeuwen
bennett
inherited
effec
european
913
SE
significantly
EGF
361
total
autocrine
antigrowth
navi
aromasin
surviving
santibanez
subfamily
antimicrotubule
development
1819
limitation
RANKL
deplete
phosphor
307
1671
factor
therapie
830
potent
get
wooster
5320
control
including
ben
LH
poly
326
car
681
SN
335
gemzar
1029
hippocampal
portion
destabilized
itself
restoration
pancreatic
carac
nat
cogen
1957
third
gression
JE
sensitization
premature
PKA
kinzler
mostly
chintharlapalli
assembly
JAK2
angiomyoli
ovarian
JF
disease
1282
lipoxygen
negative
institutional
ence
wood
jobson
GLI1
kidney
forkhead
androgen
metabolic
CG
XIAP
RANK
ppardelta
during
similaritie
FOLFOX
overexpression
afford
stromal
altered
velcade
alimta
2953
229
RG
multiple
approach
efficacy
mod
21219
blagosklonny
jaszewski
stabilization
produc
leukeran
atin
recently
sug
zumab
sprycel
305
prevention
CH
dacogen
encapsulation
neuroendocrine
aromatase
overexpressed
systemic
closely
landi
shortening
cadherin
impeding
basi
AS
wright
decreasing
BH3
homologou
druker
correlate
osteocla
discriminate
higher
lipo
kaposi
p185
nanoparticle
317
comment
mental
IK
132
malignan
ashkenazy
van
selectively
ferase
horne
phytochemical
p210
late
austin
unapproved
CDK4
votrient
sethi
pared
bech
wolanin
attenuated
bim
NIH3T3
tositumomab
dynamic
azacitidine
11611
ko
appear
rubin
significant
expressing
pat
replicating
carcinogen
die
5417
goel
abidi
univ
CA
adeno
transformed
han
hes
ester
LM
today
7292
ander
demonstrating
necessary
nam
locator
165
predict
PYK2
natural
spice
zhang
polya
chattopadhyay
cloning
inducible
147
2961
kumar
released
induced
piekarz
null
319
giordani
secretion
hepatoma
mulvey
four
ozagamicin
they
provid
robertson
chenevix
oxide
JS
cotton
hruska
PI3K
itor
344
selective
mesothelioma
inhibitor
2103
otte
reversal
investigated
chao
activi
phosphati
quintanilla
richon
MC
uct
trisenox
chemothera
117
crizotinib
tat
leu
PI3
levi
tumor
yun
HJ
336
HT
457
rafferty
FOXO
aldesleukin
383
clinic
CXC
region
according
modulatory
fibroblast
contributing
plastic
5354
superfamily
ES
modulat
phosphotidylinositol
cycle
HO
differentiation
shinojima
monoclonal
cumin
PDGFR
taniguchi
inflammation
myofibroblast
TR
ture
77030
STAT1
duvic
hydroxyl
210
suggest
lymphoblastic
tie
release
cooking
inhibiting
promotion
ethanol
continuously
glioblastoma
mdanderson
rhee
ML
hill
GSK3
cyclooxygenase
ectopic
JW
MAP
haematology
arranon
failure
25000
eribulin
disabling
dannenberg
epirubicin
blocking
BS
peroxisome
neu
FDA
mrna
main
1998
din
sasaki
271
basic
advance
pre
lympho
anticancer
RZ
mail
105
ou
dick
vonoid
aberrant
causing
player
111
lung
celecoxib
KA
protein
5410
mcdonnell
RD
geskin
action
avastin
implica
multi
istodax
GLI
migratory
JM
date
segawa
many
oxidant
causal
FH
pestalozzi
cology
FAK
progre
life
istered
catenin
herceptin
sometime
lange
vasserman
CSN5
frankel
lai
neuroblastoma
PFS
nism
ntera
expres
phorylation
TK
system
seeger
author
CK
figg
adriamycin
1553
myelofibrosi
EK
rishi
preferentially
2161
anticarcinogenic
act
968
shenk
initiated
desirable
provide
382
antiproliferation
cine
way
lacking
3863
model
fibrosarco
tic
139
tang
129
national
piwowar
20S
p27
926
ma
RAF
pilomatricoma
carfilzomib
cerubidine
admin
stand
strate
caelle
macrophage
dem
135
cyte
145
risk
tiuxetan
124
takeuchi
encoded
understanding
MPE
damaged
afinitor
phorylase
identified
chromatography
pressing
cytosolic
sig
abnormally
petrenko
inhibited
focused
oxygenase
prompting
onxol
highly
phosphorylated
mtor
gupta
similarly
523
FA
inducing
wilm
seigler
phorbol
453
PA
patient
antican
gly
mogi
benefit
351
glycoprotein
study
beside
1040
bile
ECV304
hepatology
JC
nology
affect
trexall
taxotere
ellence
chemotherapy
phosphatidylinositol
pamycin
complexe
COX
chaudhary
BL
113
family
152
raf
342
otschir
effusion
mahoney
case
341
RJ
respon
eloma
proper
variety
AG
stat3
singh
ago
YM
AN
silver
alone
jour
little
ated
BRCA
effectively
combination
surface
11606
suzuki
FEBS
1963
ras–
aggre
MDM2
focal
medulloblastoma
augment
2113
down
EGFR
osteoblast
pinchuk
120
metabolite
defined
nomoto
gastrointestinal
hormone
apoptosi
ating
dasatinib
254
prove
hamdy
relation
flynn
shim
estrogen’
combina
banik
toxic
sine
zain
51163
813
regimen
BCR
fied
peutic
menopausal
synthesi
shen
osteogenic
arsenic
hematologic
increase
lar
erivedge
HC
phenotype
SY
animal
rationale
exemestane
hood
normal
hsieh
sublethal
previou
providing
200
cetuximab
TNFα
suggested
oxalipl
matory
1352
chemosensitization
noacrylate
extra
329
JP
161
2331
somal
aggarwal
RNA
2001
edema
TX
regulating
109
published
blenoxane
ofatumumab
tive
regulator
balasubramanyam
possible
dusonchet
wan
efficiently
tetradecanoyl
majumdar
widely
schwaller
chem
frank
costly
multicenter
estrogenic
1556
derivative
genistein
HS
endogenou
jayatilake
tially
mosomal
kao
palladino
zolinza
takeda
zedoariae
transduc
hardwick
dacarbazine
metal
S52
adrucil
allen
6301
varied
containing
346
blockade
understand
pyk2
khor
diarylheptanoid
dividing
clas
proapop
ra
DM
bignell
miyamoto
huazhong
GSK
neoplastic
understood
mitra
cost
bae
active
895
biological
HDAC8
cytokine
myeloid
glucose
224
A549
choudhury
examine
chlorambucil
achieved
venting
malaysia
bak
diftitox
1982
richmond
mon
sive
426
liu
under
MI
contrast
lin
279
downregulation
garwal
vulvar
SB
1alpha
insulin
curcuma
p70s6k
molecular
mycin
cervical
abrogated
tosi
1160
our
hasima1
heterodimer
distinct
HAT
differential
canove
currently
2institute
4114
KM
MNNG
med
perturbing
1697
E2
KJ
462
2735
typically
hepatocellular
dylinositol
semiselective
autophagy
di
marian
detection
hasmeda
neo
frame
amelio
ineffective
bondada
group
promoting
guo
motion
compo
myelogenou
frye
switche
CTLA
revealed
mice
phosphorylate
AP
movement
ease
esi
AQ
meisel
modulation
large
toxicity
iressa
superior
acetyltransferase
1716
hou
accepted
293
ation
G1
acetyl
cytotoxic
neck
322
takata
469
635
reversed
modulator
nuclear
immu
macology
neuroen
kong
192
chemical
beva
treatment
catalano
sending
SP
CDK2
possessing
diferuylmethane
wilson
oth
damage
267
marlow
1892
genase
354
JAK
long
757
classified
etopopho
renner
potentiat
without
than
miralle
enha
reagent
selvendiran
become
603
effective
hepatic
department
pressor
elamin
1346
milacic
1964
zardava
hematopoietic
ditosylate
blend
8414
oforta
technolog
perennial
SV
schemme
letter
ahmed
downregulate
tion
deacetylase
tional
traditional
attrib
maley
koshikawa
effort
several
propertie
rapid
inflam
roscience
bax
pertuzumab
2000
cutaneou
repressor
AM
ryu
concentration
badmaev
p53
kirschbaum
199
mediated
transcription
generation
1979
resistance
char
manufacture
onstrate
glu
lapitinib
EA
drudi
lead
nonhistone
sil
underlying
feature
keap1
LOX
might
shinwari
bio
674
tenuation
1317
liferation
280
273
chatterjee
data
osteoclast
onco
GTD
MDA
WH
basal
vega
mechanism
131
hedgehog
wara
treat
transcriptional
314
vectibix
whose
recruit
tran
induction
icine
gested
investigative
tasi
hereditary
555
water
sarkar
necrosi
phatase
V600E
genic
2005
woo
ard
zelboraf
caov3
america
ari
acknowledgement
xeloda
kleer
tumorou
sewalt
growing
334
second
FW
difference
pathway
1997
reduc
bound
cer
transduction
nov
AB
histone
curcum
mitotic
october
yin
knuth
isofla
protect
acetate–induced
femara
kantarjian
furthermore
myristate
vitro
GR
905
mature
work
strongly
taxol
enolic
302
infliximab
weis
chen
translocate
axitinib
mucignat
HDAC1
nelarabine
acetyltran
naturally
menzie
3T3
angiopoi
adalimumab
CR
tolerance
SD
new
kazanov
mozobil
evaluation
professor
kang
linkage
org
870
fludarabine
src
PY
promote
LI
whether
eukaryotic
downstream
vital
pro
three
priyadarsini
affinity
needed
develop
ER
reference
bandelloni
adcetri
deepti
nikolskaya
2011
1891
regu
3867
che
specifically
JA
min
proline
activitie
xue
neuteboom
bose
communication
hycamtin
boctor
enhance
phosphory
epidermal
conclusion
expensive
two
376
hyperphosphor
bleo
wide
599
mecha
609
cir
paz
298
PI3’
antitumor
attenuat
dye
RE
controlling
halt
osteo
wherea
invasion
mosieniak
role
yervoy
lipoxygenase
narayan
sommer
reductase
bone
ditosyl
LS
106
gastroenterol
ixempra
2009
6r–induced
raf–positive
experi
it
maitland
occurrence
differ
wellcovorin
youne
takada
beclin
371
656
vori
tamoxifen
resulted
435
G2
wallin
MM
molec
willmore
NR
structurally
pazopanib
MR
1709
p185neu
rasheed
339
CLL
intracellular
pharmacophore
cyclind1
identification
describe
345
joe
changed
a–sensitive
half
progression
efficient
vironmental
biologic
121
adenoma
fluoroura
facchini
952
metallo
cycling
gen
khan
available
mehta
873
atherfold
demo
253
nakamura
nitrogen
chiu
bleomycin
approved
biochimica
koh
evista
block
DA
however
reversion
dase
double
179
compared
pharmorubicin
BRAF
LJ
7941817
713
degarelix
KW
metallopro
perjeta
colon
adenocarcinoma
valuable
one
biochem
muscle
1679
trend
myelocytic
lambda
mould
garcia
centurie
b–irradiated
extensive
cogene
1132
walch
DH
HEK
mtorc1
differentia
SI
turci
1538
any
external
AML
serine
2620
noma
949
site
SM
more
year
bratasz
proteasome
vexler
fo
1276
mutation
attenuate
141
24995
laboratory
ROS1
environmental
1230
song
DNA
eliminating
dar
mono
gemtuzumab
among
7490
report
GADD45
kung
considered
ADR
gonen
september
gastric
most
bush
jutooru
look
passenger
U266
JB
arterial
HETE
had
stop
migration
prostate
EMBO
immunology
chan
nega
anastrozole
807
proapoptosi
HM
focu
ical
chronic
circum
dermatology
gallo
activate
RTK
potentiate
effector
KK
divi
waly
phar
FASEB
sitivity
SH
denning
competitive
bination
kin
light
pacli
451
WD
tobioka
kuo
marai
interacting
vepesid
methoxy
BID
cervello
dou
still
shang
bierie
will
phase
325
xie
prolifera
tofacitinib
PTEN
skin
part
fa
compound
tively
differen
erwise
861
cytochrome
inhi
targretin
337
paradigm
lymphoma–associated
arrest
helical
aortic
rathinasamy
CC
yeh
RAS
stetler
seen
plagued
future
tuberou
cause
carcinoma
drug
966
upon
si
verma
only
very
“smart
soluble
gardner
nitro
neurotoxicity
tensin
moon
fect
usually
tar
GM
higashiyama
enzyme
ase
problem
colorectal
MCF
d’alessandro
proliferator
nm23
walker
GADD153
arachidonic
component
lonardi
fox
anand
HT22
uncontrolled
qimron
daunorubicin
TS
barni
CD33
lymphocyte
ransom
BB
pegintron
transforming
193
288
park
cyclo
119
GNRH
thereby
bcr
jee
nephrine
epub
weber
prognostic
yao
strong
MF
2169
bined
campath
taxel
extracellular
approache
IFN
internation
thymidylate
adhesion
DU
189
cisplatin
interferon
gemcitabine
into
seven
advanced
107
keratinocyte
making
bharne
ewing
journal
p27kip1
depen
dependent
ratio
1424
strader
417
bharat
trophoblastic
cil
rumbail
curti
MS
oncaspar
EC
sclerosi
yokoyama
cetux
state
tal
144
lary
gestational
highlighted
apeutic
sand
pharmaceutic
inflamma
ring
samara
sakaguchi
prompted
hela
associated
ular
direct
CDK
retinoid
prasad
triggering
bortezomib
phenotypic
antiprolifera
cumstance
ALK
highlight
EZH2
DF
granuloma
thyroid
blood
874
folate
involving
increasing
george
viru
NHL
ARNT
chemopre
haematologica
ven
pros
21206
pegaspargase
alkylating
CD30
phosphoryla
due
1993
testicular
newman
woffendin
cur
tiplying
633
sun
introduction
151
1977
castration
increased
frequent
kivlin
ferrell
hartman
isopepti
six
1952
UM
tarabine
dhawan
etoposide
independent
dephosphorylated
reddy
zeste
CT
tyrosine
1549
carci
received
515
lupron
xgeva
MMP
activat
alemtuzumab
138
p34cdc2
tykerb
suh
fibrosarcoma
oncol
food
nexavar
often
polyak
limtrakul
factor–1
LA
next
biochim
almost
tarceva
ramachandran
aderka
tumorigenesi
similar
togari
profoundly
constitutive
indice
AD
RA
110
ic
upa
1995
leukemia
333
toward
polyphenol
finding
rubicin
floyd
iib
chromophobe
evaluated
stafford
antiangiogenic
same
8861
lipigorngoson
science
fac
rich
mul
anti
meth
progressive
embryonic
ETS2
CS
LX
prostaglandin
revlimid
koshihara
1288
shail
sen
tseng
p21cip1
hengst
1559
temozolomide
phospholipase
uted
pression
suppressed
biophysica
1937
pharmacol
inflammatory
ramo
renal
transition
nude
rat
compromising
transformation
acti
yatabe
facilitiated
JH
oxidative
prolia
some
function
hong
trioxide
cort
HW
nilotinib
nitrosoguanidine–mediated
janu
cya
processe
cabazitaxel
promoter
immunodeficiency
methyl
chanan
doxoru
herb
evi
modulate
6072
kemia
spread
osteoporosi
expressed
non
antioxidant
given
against
ensure
877
pae
TSC
gong
crohn
analysi
carefully
bind
ranjan
TL
ipilimumab
ahn
hargrave
chain
tetrahydrocurcumin
nagabhusha
mesylate
tance
IM
130
chu
denosumab
plex
cuminoid
article
xia
begin
inside
ability
noxa
between
WK
transc
manson
upregulating
symptom
591
NF
lovo
func
cytosar
docrine
tosylate
UVB
DJ
tetrahydrocurcum
102
mito
isakson
threonine
kanwar
modulating
DP
voorhee
acetylation
MA
selling
shishodia
acac
jaffe
YZ
positive
lation
pritchard
carter
fusion
clegg
bigner
attack
347
KR
suppressor
maruyama
vismodegib
YH
acute
ligand
CDK6
enable
ergistic
rapidly
axi
bevacizumab
dose
TH
jin
com
midou
thought
trial
remove
letrozole
offer
cheung
proliferative
kill
clonal
astrocytoma
inde
TO
2010
palmieri
QP
YC
BJ
lapatinib
819
microtubule
publication
140
henry
FM
www
women
954
looked
protease
doe
beever
panda
correlative
okochi
controlled
matulane
chromo
synergisti
yosef
cao
CD20
dislodged
extrinsic
donato
abundant
HH
pleural
pattern
chauhan
fully
oncovin
why
product
AKT
destruction
transactivation
nitric
cjun
duong
kalai
break
antitu
zevalin
course
CD24–
K562
inhibi
behaviour
eration
subbaramaiah
115
variou
377
lowered
STAT3
presse
mitochondrial
ekmekcioglu
mol
must
ulator
specific
temsirolimu
body
telomere
sed
multiforme
docefrez
identi
internal
studie
WC
ayyappan
able
seiden
8427
hwang
myelodysplastic
chuang
inhibition
xiaoling
poma
COX1
shipley
path
using
single
signal
JY
american
egr
concurrent
nogenesi
naling
XC
melanoma
since
advantage
platelet
critical
oxaliplatin
338
concept
1996
upregulated
nonn
jung
1415
ing
occurred
involved
corrected
united
other
SL
lid’
bcl
1196
cultured
metastatic
sale
turmeric
328
122
fuqua
878
perri
characteriza
269
investigator
monother
muta
intact
puliappadamba
university
pendent
arimidex
autophagic
permanently
PM
topoi
poxygenase
AC
compare
another
NIH
nimnual
aggressive
vein
target
dubiel
phospha
125
pralatrexate
2152
1188
formation
2008
refractory
GJ
ship
313
thera
klinger
raji
initiation
CW
nificance
ifosfamide
elicited
aboussekhra
manuscript
specificity
cally
cossu
hung
SA
AJ
bexarotene
pase
deng
osteoblastic
xalkori
ther
overcoming
peripheral
organ
nutr
vascu
malate
within
MJ
pesticide
chirnoma
disrupt
llui
lopez
kurzrock
imatinib
soft
stres
slingerland
concluded
ferent
jun
186
2–positive
banerjee
vorinostat
genetic
CREB
potten
declare
1986
enhanced
51171
proceeding
2004
stratton
dumdey
1551
rink
stenner
bueso
bottomley
baek
vandetanib
estrogen
monoace
response
monocytic
papineni
fludara
well
PKC
sengupta
neu–positive
357
because
recent
preventing
chemistry
velban
potential
steinberg
EJ
denileukin
vinblastine
rhim
liao
row
erase
curcumin’
moragoda
mose
decade
cellular
level
kap
AIDS
abl
resistant
stevenson
none
unreg
nair
HE
eloxatin
hypoxia
CJ
patel
derich
doxorubicin
regulated
adenocar
spite
catalytic
radiosensitiza
occurring
1978
faculty
linked
ble
nutrition
VT
decrea
vogelstein
gilroy
NPI
antagonist
salgia
cytarabine
hawe
gierse
bition
hodgkin
JJ
arber
RK
neutrophil
irritant
mar
unbalanced
killer
noz
hendrayani
tastasi
spin
annal
hoque
kinase
deubiquitinating
cie
world
notarbartolo
varier
disorder
decrease
cytotoxicity
marker
dvory
prominent
chromosome
early
experimental
osmot
799
cient
biochimi
trade
tential
1042
II
1955
kda
capecitabine
cinogen
ideal
translocation
BC
118
959
form
HER
mckenna
IGF
358
joske
331
nal
longer
cyclin
surprising
teague
survival
chro
194
them
isoform
shankar
7283
hyperproliferative
XS
hint
liposomal
smooth
used
equilibrium
figure
lymphoma
chaturvedi
YF
true
vent
being
monocyte
docetaxel
december
polymerase
oncogene
totic
rituximab
examined
microglia
ongoing
necessitating
when
platania
ulated
responsible
MG
SR
decitabine
xenograft
fos
derived
YY
man
lysz
5947
inhibitory
rivera
ve
incidence
rhizoma
chalandon
peginterferon
STAT
choi
1999
418
may
dynam
osteosarcoma
re
analogue
medicinal
sutent
sensitized
348
hall
different
gilfillen
functional
789
esophageal
cyto
tani
phosphorylation
reveal
terminal
addres
HL
downregulated
bloodstream
crucial
CD24
PUMA
388
vaidya
novel
apy
varambally
synergistic
azoxymethane
served
spe
IL
RC
acetate
camptosar
malignant
thu
7498
therapeu
vincristine
beta1
solid
VEGFR1
lett
richardson
oncogenic
folic
further
637
longa
marusyk
disrupting
contributor
regulat
evidenced
change
parra
butyl
immunohistochem
lev
jiang
tylcurcumin
379
mansour
epithelial
tase
TGF
1536
1639
1035
toxicology
int
number
activa
aggarwal1
endothelial
papil
liewen
295
usefulnes
acetylate
error
arduino
dinarello
apoptotic
MK
degrade
called
organization
exter
zheng
relevance
ca
karmakar
nent
reg
angio
3871
procarbazine
tiplication
adjacent
produce
sev
NL
foresti
step
regulation
schade
3115
100
ISSN
how
MB
event
restenosi
VEGF
KD
homology
curcu
6308
kofide
their
voghera
mutant
best
calyculin
ghatak
hut
diated
605
therefore
administration
treanda
tated
oxygen
oncoprotein
abarelix
gleevec
inactiva
promising
metastasi
sel
mutated
capacity
point
coneogenic
hindi
8852
DW
SK
171
leucovorin
eral
2609
lade
IJBMB1209004
oncology
cesse
445
liver
required
6079
FOS
martinez
immunophilin
methotrexate
tyro
also
2012
piwocka
LC
huang
1884
tissue
eligard
chadalapaka
related
WS
cancer
cox
diagnostic
degrading
but
too
alam
small
biol
therapeutic
over
motterlini
koiwai
divide
duced
found
webb
angiogenesi
diverse
leuprolide
expre
merase
henklein
association
induce
IκBα
sonic
cascade
prevent
discoverie
tor
CXCL12
dietary
TM
ineffec
kweon
endometrial
inoue
polymerization
premalatha
yoshida
gefitinib
matrix
1295
like
otrexate
paw
3281
sup
CD52
shipitsin
CML
immunopharmacol
camp
ERK2
valdecoxib
hydroxy
BMC
khafaga
ALL
leukotriene
noor
hemeoxy
bolu
elliott
antiapoptotic
especially
include
ha
sorafenib
marrow
suppression
unlikely
WJ
352
arzerra
low
evidence
glutathione
kwon
126
kiefer
activated
cho
651
laskin
through
while
aryl
scription
flavell
rituxan
caused
HER2
inlyta
gene
clear
887
retinoblastoma
sagi
ERK
jungblut
ptpase
500
thesi
toremifene
918
clast
conflict
CE
brentuximab
developed
pivotal
PC
cleavage
MC3T3
tasigna
inva
bloushtain
8234
bullet
modu
kuramochi
AL
XL
invasive
anuchapreeda
prolif
pharmacological
represse
collagenase
dicken
FU
COP9
1994
jakafi
mukhopadhyay
posses
germ
ventive
inos
try
UPS
vessel
WAF1
AMPK
pri
vejda
compara
paterson
zhong
greater
such
FLICE
loproteinase
shape
romidepsin
150
chua
wang
carrageenan
245
signalsome
persistent
analog
jang
dy
current
irinotecan
vincasar
example
decreased
translocator
332
discussed
accumulation
synergism
SO
fanconi
present
immuno
minimal
successfully
clolar
lenalidomide
hepato
1547
statement
antimetastatic
tein
ultraviolet
tournier
combining
member
MT
constitutively
ray
etin
mediate
JR
dome
separa
PKB
ficiency
zhou
elevated
ate
stem
time
phosphoinositide
maintain
diferulolylmethane
retard
PJ
IC
ment
downregulating
exhibit
signalosome
topotecan
ixabepilone
cyclic
either
common
114
DD
health
designated
COX2
BA
journ
irra
altorki
chemokine
son
human
tern
yasunaga
812
review
restore
monahan
karunagaran
cheng
somatic
duce
hepatocyte
interfere
coregulator
gahlot
rated
migra
NSCLC
noncompetitive
firmagon
prone
henke
kaneko
sang
urokinase
tan
erlotinib
dexamethasone
104
boland
scientific
HDAC
complex
dysregulation
gent
haye
hacat
transcrip
cell
zortres
CXCL
five
domain–
phone
5332
showed
aggarw
knockout
international
270
G0
KH
mor
1602
upstream
proliferation
tomlin
pemetrexed
2007
anto
signaling
leung
academy
defect
list
2164
jou
MO
bendamustine
proto
yang
1008
dunn
element
ticancer
modified
receptor
103
cinu
201
marshall
asparagine
PPARδ
macro
kobayashi
VEGFR
eicosatetraenoic
ST
carcinogenesi
KS
inflammato
section
size
domain
torisel
production
srivastava
angiogenic
malignancie
tin
zeng
hep
1219
potentiation
“targeted
cinoma
riggin
KIP1
JNK
side
6738
neural
inactive
VM
JD
fluorouracil
DUB
davie
ncer
tiation
biophy
acterization
tentiate
applica
acting
enough
phytochemistry
GH
galardy
bolic
homolog
26S
modern
consequence
kennedy
E1
safety
acid
143
dif
use
2323
unlike
BK
pretreated
effi
1497
518
arachidon
stimulate
yel
activating
2155
411
50603
switched
kucuksayan
478
ste
experimen
hudson
moul
paradox
1888
abl–expressing
marizomib
catastrophe
2286
majority
fardini
takahashi
hughe
ABL
hallmark
name
resi
“magic
rapamycin
231
akt
photidylinositol
arise
davi
box
343
epi
therapy
recep
aschele
involvement
remicade
pan
suga
attacked
trastuzumab
857
unsaturated
bicin
con
scott
NB
protea
platinol
investigation
chitosan
andreadi
existing
mammalian
receptorδ
soltamox
altaf
manifest
metastase
siddiqi
hua
rep
require
leon
lecular
stephen
p300
murine
CB
acta
colo205
requirement
erbitux
essential
basu
JK
RAF’
cui
pharmacology
mouse
precursor
nikolsky
safe
head
AKT8
inactivated
yielded
seol
magrisso
zambrowicz
antigen
ligase
caprelsa
sin
172
RL
mujtaba
223
CBP
JUN
marotta
observed
huh
lncap
anderson
hydrocarbon
lumpur
chun
ibritumomab
suppresse
retinoblasto
growth
sikora
kunnumakkara
highest
1137
established
balogun
BH
premenopausal
D1
WF
AR
numerou
via
BR
gordon
tenance
penn
ubiquitou
cofactor
8230
geting
reproduction
giogenesi
syndrome
binding
cannot
simultaneou
not
salinosporamide
meta
regulatory
kim
kundu
CXCL12–CXCR4
kuzel
SS
multitar
phoma
flanagan
biotechnology
mylotarg
imab
brain
activation
xeno
SF
releasing
tory
remain
onset
interleukin
division
range
phenyl
inactivation
carrier
rhabdomyo
root
erbb
133
biolo
teinase
123
MCF10A
effect
beta
nucleu
peehl
reduced
caretta
repair
prod
siddappa
strier
osteoclastogenesi
1828
AK
counter
deg
administering
potentiated
lee
search
specie
shapiro
factor–kappab
3rd
perspective
vemurafenib
folotyn
dle
before
catalyze
anti–mitotic
replication
fareston
selec
134
3290
immortalized
abstract
ishidoh
major
implicated
primary
phenolic
high
help
demonstrated
USA
sensitizing
destroy
exploration
combined
first
immunol
185
patchva
lymphocytic
play
enhancer
modulated
sub
HZ
structure
hahn
2003